目的 觀察蘇黃止咳膠囊和布地格福吸入氣霧劑聯(lián)合治療老年緩解期慢性阻塞性肺疾?。–OPD）患者的臨床療效。方法 選取2024年3月—2025年2月首都醫(yī)科大學附屬北京積水潭醫(yī)院老年內(nèi)科、呼吸內(nèi)科、全科醫(yī)療科、干部科收治的96例老年緩解期COPD患者，依據(jù)組間匹配原則將患者分為對照組和治療組，每組各48例。對照組給予布地格福吸入氣霧劑，2撳/次，2次/d。治療組在對照組治療基礎(chǔ)上口服蘇黃止咳膠囊，3粒/次，3次/d。兩組均連續(xù)治療6周。觀察兩組治療效果，比較兩組血清炎癥因子[白細胞介素-17（IL-17）、白細胞介素-8（IL-8）、腫瘤壞死因子-α（TNF-α）、C反應(yīng)蛋白（CRP）]、肺功能相關(guān)指標[呼吸峰流速（PEF）、最大呼氣壓（MEP）、第1秒用力呼氣容積（FEV1）、FEV1/FVC]、氧化應(yīng)激反應(yīng)指標[丙二醛（MDA）、超氧化物歧化酶（SOD）、還原型谷胱甘肽（GSH）]、COPD評估測試（CAT）問卷評分。結(jié)果 治療后，治療組總有效率是97.92%，顯著高于對照組的79.17（P＜0.05）。治療后，兩組IL-17、IL-8、TNF-α、CRP均較同組治療前顯著降低（P＜0.05）；治療后治療組IL-17、IL-8、TNF-α、CRP均低于對照組（P＜0.05）。治療后，兩組PEF、MEP、FEV1、FEV1/FVC均升高（P＜0.05）；治療后，治療組PEF、MEP、FEV1、FEV1/FVC高于對照組（P＜0.05）。治療后，兩組MDA下降，而SOD、GSH升高（P＜0.05）；治療后，治療組MDA低于對照組，SOD、GSH高于對照組（P＜0.05）。治療后，兩組CAT均較同組治療前顯著下降（P＜0.05）；治療后，治療組CAT低于對照組（P＜0.05）。結(jié)論 蘇黃止咳膠囊聯(lián)合布地格福吸入氣霧劑可提高老年緩解期COPD患者臨床療效，糾正炎癥狀態(tài)，改善氧化應(yīng)激反應(yīng)，增強肺功能，對提高患者生活質(zhì)量指數(shù)也有益。

Objective To investigate the therapeutic effect of Suhuang Zhike Capsules combined with budigafol in treatment of remission period of chronic obstructive pulmonary disease in the elderly. Methods A total of 96 elderly patients with COPD in remission who were admitted to the Department of Geriatrics, Department of Respiratory Medicine, Department of General Practice and Department of Cadre Medicine of Beijing Jishuitan Hospital, Capital Medical University from March 2024 to February 2025 were selected. According to the principle of matching between groups, the patients were divided into control group and treatment group, with 48 cases in each group. Patients in control group were given Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol, 2 puffs each time, twice daily. Patients in treatment group took orally Suhuang Zhike Capsules on basis of treatment in control group, 3 capsules each time, 3 times daily. Both groups were treated continuously for 6 weeks. The therapeutic effects of two groups were observed. The serum inflammatory factors (IL-17, IL-8, TNF-α, CRP], pulmonary function-related indicators (PEF, MEP, FEV1, FEV1/FVC), oxidative stress response indicators (MDA, SOD, GSH), and CAT score were compared between two groups. Results After treatment, the total effective rate of treatment group was 97.92%, significantly higher than that of control group (79.17) (P < 0.05). After treatment, the levels of IL-17, IL-8, TNF-α, and CRP in both groups were significantly lower than those before treatment in same group (P < 0.05). After treatment, the levels of IL-17, IL-8, TNF-α, and CRP in treatment group were all lower than those in control group (P< 0.05). After treatment, PEF, MEP, FEV1, and FEV1/FVC in both groups increased (P < 0.05). After treatment, the PEF, MEP, FEV1, and FEV1/FVC in treatment group were higher than those in control group (P < 0.05). After treatment, MDA decreased in both groups, but SOD and GSH increased (P < 0.05). After treatment, MDA in treatment group was lower than that in control group, but SOD and GSH were higher than those in control group (P < 0.05). After treatment, CAT score in both groups decreased significantly compared with that before treatment in same group (P < 0.05). After treatment, the CAT score of treatment group was lower than that of control group (P < 0.05). Conclusion Suhuang Zhike Capsule combined with budigafol can improve the clinical efficacy of elderly patients with COPD in remission, correct the inflammatory state, improve oxidative stress response, enhance lung function, which is also beneficial for improving life quality of patients.

R974

國家重點研發(fā)計劃項目（2020YFC2005400）；北京市中醫(yī)藥科技項目（BJZYYB-2023-34）